<DOC>
	<DOCNO>NCT02572752</DOCNO>
	<brief_summary>To establish bioequivalence 1 soft gelatine capsule contain 200 mg nintedanib compare 2 soft gelatine capsule contain 100 mg nintedanib</brief_summary>
	<brief_title>Relative Bioavailability 2 Oral Formulations Nintedanib</brief_title>
	<detailed_description />
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male subject accord investigator assessment , base complete medical history include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test . 2 . Age 18 50 year ( incl . ) 3 . Body weight least 70 kg 4 . BMI 21 31 kg/m2 ( incl . ) 5 . Signed date write informed consent prior admission study accordance GCP local legislation 6 . Male subject , willing use medically acceptable method contraception first 3 month administration nintedanib . Acceptable method contraception use male volunteer include sexual abstinence , vasectomy perform least 1 year prior dose barrier contraception ( condom ) . Subjects , vasectomise sexually abstinent ensure additional acceptable method contraception use female partner IUD ( intrauterine device ) , surgical sterilisation ( include hysterectomy ) , hormonal contraception ( e.g . implant , injectables , combine oral vaginal contraceptive ) start least 2 month prior first nintedanib administration , barrier method ( e.g . diaphragm spermicide ) . Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator 2 . Repeated measurement systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg , pulse rate outside range 45 90 bpm 3 . Any laboratory value outside reference range investigator considers clinical relevance 4 . Any evidence concomitant disease judge clinically relevant investigator 5 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 6 . Cholecystectomy and/or surgery gastrointestinal tract could interfere pharmacokinetics trial medication ( except appendectomy simple hernia repair ) 7 . Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder 8 . History relevant orthostatic hypotension , faint spell , blackouts 9 . Chronic relevant acute infection 10 . History relevant allergy hypersensitivity ( include allergy trial medication excipients ) 11 . Intake drug long halflife ( 24 h ) within 30 day less 10 halflives respective drug prior administration trial medication 12 . Within 10 day prior administration trial medication , use drug might reasonably influence result trial 13 . Participation another trial investigational drug administer within 60 day prior plan administration trial medication 14 . Smoker ( 10 cigarette 3 cigar 3 pipe per day ) 15 . Inability refrain smoke specify trial day 16 . Alcohol abuse ( consumption 30 g per day male ) 17 . Drug abuse positive drug screen 18 . Blood donation 100 mL within 30 day prior administration trial medication intend donation trial 19 . Intention perform excessive physical activity within one week prior administration trial medication trial 20 . Inability comply dietary regimen trial site 21 . Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>